Evolocumab (Repatha) has been shown to reduce the risk of a first major cardiovascular event in patients with diabetes not diagnosed with atherosclerosis. This conclusion comes from the VESALIUS-CV substudy. The drug belongs to the group of PCSK9 inhibitors. The study indicates a potential benefit of evolocumab treatment even in diabetics without proven atherosclerosis.